Physician profile
Billy Back
NPI 1831191444
$1,788.06
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $233 · 2021: $484 · 2022: $374 · 2023: $243 · 2024: $14.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $474.20 | 2019-2023 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $194.13 | 2019-2021 | |
| Pfizer INC. | $138.71 | 2019-2023 | |
| Novo Nordisk INC | $103.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.34 | 2021-2022 | |
| Amarin Pharma, INC. | $89.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $82.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $79.96 | 2019-2023 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $69.59 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.59 | 2019-2022 | |
| Abbvie INC. | $61.98 | 2022-2023 | Vraylar, Viberzi, Linzess |
| Amgen INC. | $58.40 | 2019-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.15 | 2019-2023 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $45.77 | 2019-2020 | |
| Lilly USA, LLC | $45.15 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.96 | 2019 | |
| Boston Scientific Corporation | $30.29 | 2023 | Watchman Access System |
| Philips North America LLC | $14.82 | 2024 | (Ck4) Mcot |
| Sunovion Pharmaceuticals INC. | $13.80 | 2019 | |
| Athena Bioscience, LLC | $12.63 | 2023 | Nexiclon Xr |
| Eisai INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Back listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.